Stryker Corp
NYSE:SYK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (23.9), the stock would be worth $396.44 (21% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 19.8 | $327.51 |
0%
|
| 3-Year Average | 23.9 | $396.44 |
+21%
|
| 5-Year Average | 23.9 | $396.07 |
+21%
|
| Industry Average | 12.9 | $213.48 |
-35%
|
| Country Average | 14.4 | $237.84 |
-27%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$156.8B
|
/ |
Jan 2026
$6.9B
|
= |
|
|
$156.8B
|
/ |
Dec 2026
$8B
|
= |
|
|
$156.8B
|
/ |
Dec 2027
$8.8B
|
= |
|
|
$156.8B
|
/ |
Dec 2028
$9.7B
|
= |
|
|
$156.8B
|
/ |
Dec 2029
$10.7B
|
= |
|
|
$156.8B
|
/ |
Dec 2030
$11.8B
|
= |
|
|
$156.8B
|
/ |
Dec 2031
$12.9B
|
= |
|
|
$156.8B
|
/ |
Dec 2032
$14.2B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 19.8 | 38.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 45.5 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 13.8 | 25.2 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 12.9 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 18.9 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 10.7 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 24.9 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 30.1 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 9.8 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 15.1 | 21.6 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
31.4B USD | 10.9 | 15.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Stryker Corp
Glance View
Stryker Corporation, a pioneering force in the medical technology industry, traces its roots back to the innovative spirit of Dr. Homer Stryker, an orthopedic surgeon whose dissatisfaction with existing medical equipment spurred him to improve them. Founded in 1941, the company initially focused on new medical devices that addressed specific problems faced by healthcare practitioners. Over the decades, Stryker has evolved into a diversified powerhouse with a portfolio that spans a wide range of products, including joint replacements, surgical equipment, neurotechnology, and spine care solutions. This evolution came through strategic acquisitions and relentless innovation, allowing Stryker to meet the ever-increasing demands of a dynamic healthcare landscape. The company's business model thrives at the intersection of technology and healthcare. With their cutting-edge research and development capabilities, Stryker consistently pushes the envelope in creating sophisticated products that enhance patient outcomes. Revenue streams are predominantly generated from the sale of medical and surgical equipment as well as a myriad of implantable surgical devices used in orthopedic procedures. Stryker’s instruments and solutions are staples in hospitals and clinics worldwide, driven by their commitment to quality and efficacy. Additionally, the company's astute investments in advanced robotics and digital health technologies have positioned it well within the burgeoning field of precision medicine, providing lucrative opportunities to deepen its market entrenchment and expand its competitive edge.
